1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 2:Demand for thrombolysis in the United States based on the published literature
Report Cases per Year per Hospital* Intra-arterial treatment, multicenter trials PROACT, 19989 1 (0–10) PROACT II, 19996 1 (0–17) EMS, 199966 5 (2–10) IMS-I, 20048 7 (0–27) MERCI, 20057 3 (0–9) IMS-II, 20075 2 (NA) Multi MERCI, 20084 5 (0–20) Intra-arterial treatment, single center Barnwell et al, 199419 7 Suarez et al, 199918 15 Jahan et al, 199967 5 Ernst et al, 200020 17 Hill et al, 200221 4 Ramee et al, 200468 3 Choi et al, 200622 9 Devlin et al, 200723 30 Kim et al, 200717 13 Wolfe et al, 200816 15 Intravenous treatment, multicenter trials NINDS, 199569 20 ATLANTIS, 199970 1 STARS, 200071 4 Intravenous treatment, single center Chiu et al, 199872 30 Zweifler et al, 199873 9 Grotta et al, 200174 61 Kahn et al, 200575 26 Wolfe et al, 200816 45 Arenillas et al76 46
Note:—PROACT indicates Prolyse in Acute Cerebral Thromboembolism trial; EMS, Emergency Management of Stroke trial; IMS, Interventional Management of Stroke trials; MERCI, Mechanical Embolus Removal in Cerebral Ischemia trials; NINDS, National Institute of Neurological Disorders and Stroke; ATLANTIS, Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke trial; STARS, Standard Treatment with Alteplase to Reverse Stroke study.
* Numbers in parentheses are ranges.